News
REGMF
10.93
NaN%
--
RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products
TipRanks · 09/02 11:43
CICC Sticks to Its Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 09/01 05:05
SPDB Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 08/28 06:05
Morgan Stanley Sticks to Their Hold Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 08/28 00:37
UBS Remains a Buy on RemeGen Co. Ltd. Class H (9995)
TipRanks · 08/28 00:36
Citi Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 08/26 11:05
RemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones
TipRanks · 08/24 15:14
RemeGen Sets Out Board Structure and Key Governance Committees
TipRanks · 08/24 15:13
RemeGen Commits US$100 Million of Idle Funds to OCBC Wealth Products in Discloseable Transaction
TipRanks · 08/18 12:38
Daiwa Keeps Their Buy Rating on RemeGen Co. Ltd. Class H (9995)
TipRanks · 08/14 00:26
J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)
TipRanks · 08/08 00:26
RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal
TipRanks · 08/05 11:39
RemeGen Co. Ltd. Class H (9995) Gets a Buy from CMBC International
TipRanks · 08/01 05:05
Nomura Keeps Their Hold Rating on RemeGen Co. Ltd. Class H (9995)
TipRanks · 07/28 00:26
RemeGen Deploys Idle Funds Into SPDB Wealth Products in Discloseable Transaction
TipRanks · 07/02 12:38
RemeGen Shareholders Back All Resolutions at 2025 AGM
TipRanks · 06/16 14:40
RemeGen Clarifies Board Composition and Committee Roles
TipRanks · 06/16 14:39
J.P. Morgan Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 06/11 00:27
RemeGen Co. Ltd. Class H (9995) Gets a Buy from UBS
TipRanks · 06/10 00:25
RemeGen Wins Conditional China Nod for Telitacicept in IgA Nephropathy
TipRanks · 06/08 12:45
More
Webull provides a variety of real-time REGMF stock news. You can receive the latest news about Remegen through multiple platforms. This information may help you make smarter investment decisions.
About REGMF
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.